iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Rhea-AI Summary
iBio (NASDAQ: IBIO) reported preclinical body composition data for IBIO-610 in obese non-human primates showing a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass after two once-every-eight-week doses, with a slight uptick in lean mass.
iBio also reported an extended 33.2-day half-life in obese NHPs and a projected human half-life up to 100 days, supporting potential twice-yearly dosing; full dataset and additional biomarker analyses will be presented at scientific conferences in 2026.
Positive
- Visceral fat reduced by 6.7% in obese NHPs
- Total fat mass reduced by 5.2% in obese NHPs
- Projected human half-life of up to 100 days, supporting potential twice-yearly dosing
Negative
- Study was small and not statistically powered, limiting confidence in effect size
News Market Reaction – IBIO
On the day this news was published, IBIO declined 4.21%, reflecting a moderate negative market reaction. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $86M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Biotechnology showed mixed moves, with EVAX and PULM down while LEXX and GOVX were up. Momentum scanner flagged NBY and LSTA moving up, but with no same-direction cluster tied to this obesity data, action appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Conference participation | Positive | +0.8% | Participation in two investor conferences with management fireside chats and meetings. |
| Feb 10 | Earnings and update | Negative | -2.6% | Q2 FY2026 loss and no revenue alongside PIPE financing and pipeline progress. |
| Jan 09 | Private placement | Negative | +14.9% | Announcement of <b>$26M</b> private placement to fund obesity and cardiometabolic programs. |
| Nov 24 | Conference announcement | Positive | +5.4% | Evercore conference appearance highlighting obesity pipeline and NHP data for IBIO‑610. |
| Nov 12 | Earnings and financing | Negative | -8.0% | Q1 FY2026 results with larger loss and a <b>$50M</b> warrant offering for up to <b>$100M</b>. |
Recent news has often aligned with price direction: conference and financing updates tended to see positive or modest gains, while earnings and higher losses coincided with declines. A prior private placement was a notable outlier, drawing a strong positive reaction despite potential dilution.
Over the past few months, iBio has combined financing, pipeline updates, and conference visibility. A $50.0M offering with up to $100.0M potential proceeds and a later $26M private placement strengthened cash and extended runway. Conferences in Nov 2025 and Feb 2026 highlighted IBIO‑610’s obesity data and next‑generation pipeline. Earnings on Nov 12, 2025 and Feb 10, 2026 underscored larger losses but also preclinical progress. Today’s NHP body composition data continues that focus on IBIO‑610’s fat‑selective profile.
Regulatory & Risk Context
An effective Form S-3 shelf dated February 27, 2026 allows iBio to offer up to $200,000,000 of securities, including up to $100,000,000 of common stock via an Open Market Sales Agreement with Jefferies. A 424B5 filing on March 6, 2026 activated an at-the-market program, indicating capacity for incremental equity issuance as market conditions permit.
Market Pulse Summary
This announcement highlights preclinical NHP data showing IBIO‑610 reduced visceral fat by 6.7% and total fat mass by 5.2%, with an extended half‑life projected up to 100 days in humans and a fat‑selective profile. Historically, iBio has paired similar updates with financings that strengthened its balance sheet. Investors may watch for future clinical trial initiations, additional biomarker readouts, and use of the effective Form S‑3 and $100,000,000 ATM program as the obesity pipeline advances.
Key Terms
non-human primate medical
activin e medical
half-life medical
biomarkers medical
siRNA medical
AI-generated analysis. Not financial advice.
Study demonstrated reduction of
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate.
The preclinical body composition data demonstrates IBIO-610 reduced fat mass in obese NHPs compared to vehicle-treated obese NHPs, in a small, not statistically powered study. Following two once-every-eight-week dosing, IBIO-610 reduced visceral fat by
“These data reinforce IBIO-610’s potential to deliver fat-selective improvements in body composition while maintaining lean mass,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “When added to the previously demonstrated extended half-life, these results further confirm the potential of IBIO-610 as a first-in-class therapy, and the capability of our AI-enabled discovery platform to address complex targets obesity, cardiometabolic and cardiopulmonary diseases, and may significantly improve the lives of patients.”
Previously reported data from the study demonstrated IBIO-610’s extended 33.2-day half-life in obese NHPs and a projected human half-life of up to 100 days, supporting the potential for convenient, twice-yearly dosing. The complete dataset, which will include analysis of additional biomarkers, will be presented by iBio at scientific conferences throughout 2026.
“These findings are consistent with body composition effects reported for therapies targeting the Activin E pathway, including human siRNA approaches,” said Cory Schwartz, Ph.D., Director of Research and Early Development at iBio. “We believe IBIO-610’s fat-selective biology supports its potential to drive targeted fat loss while maintaining lean mass. Our team is continuing its thorough analyses of the dataset spanning metabolic, biomarker, and mechanistic endpoints, and we look forward to presenting additional insights.”
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the therapeutic potential of Activin E as a target for cardiometabolic disorders and obesity; the capability of iBio’s AI-enabled discovery platform to address complex targets in cardiometabolic, obesity and cardiopulmonary diseases and significantly improve the lives of patients; the presentation by iBio of the complete dataset, which will include analysis of additional biomarkers, at scientific conferences throughout 2026; the potential of IBIO-610’s fat-selective biology to drive targeted fat loss while maintaining lean mass; iBio’s ability to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases and other hard-to-treat diseases; iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of Activin E to be a successful target for cardiometabolic disorders and obesity and iBio’s antibody to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; iBio’s ability to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases and other hard-to-treat diseases; iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the Securities and Exchange Commission (the “SEC”) including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
What body composition changes did IBIO-610 produce in the March 9, 2026 NHP study for IBIO?
Does iBio report a human dosing advantage for IBIO-610 (IBIO) based on the NHP data?
How robust are the IBIO-610 preclinical results reported by iBio (IBIO) on March 9, 2026?
How does IBIO-610’s fat-selective profile compare to other Activin E pathway approaches for IBIO investors?
When will iBio (IBIO) present the full IBIO-610 dataset and additional biomarker analyses?
